From: Radiation and breast cancer: a review of current evidence
 | No. of women | No. of breast cancers |  |  |  | ||
---|---|---|---|---|---|---|---|
Cohort | Exposed | Non-exposed | Exposed | Non- exposed | Breast dose (Sv)b | Exposure age (years)b | ERR at 1 Svg |
Atomic bombings | Â | Â | Â | Â | Â | Â | Â |
   Life Span Study, Japan [43] | 70,165 | c | 1059 | - | 0.28 | 27 | 1.74 |
Diagnostic radiation | Â | Â | Â | Â | Â | Â | Â |
   Tuberculosis fluoroscopy, Canada [27]a | 31,917 | c | 319 | 332 | 0.89 | 26 | 0.90 |
   Tuberculosis fluoroscopy, USA [28] | 2573 | 2367 | 147 | 87 | 0.79 | 26 | 0.40 |
   Scoliosis, USA [29]a | 4929 | 644 | 70 | 7 | 0.11 | 10 | 5.4 |
Radiotherapy for benign disorders | Â | Â | Â | Â | Â | Â | Â |
   Enlarged thymus, USA [30] | 1201 | 2469 | 22 | 12 | 0.69 | <1 | 2.39 |
   Skin hemangioma, Sweden [31] | 17,202 | c | 245 | - | 0.29 | 0.5 | 0.35 |
   Tinea Capitis, Israel [32] | 5400 | 8100 | 25 | 27 | 0.02 | 7 | - |
   Benign breast disease, Sweden [33] | 1216 | 1874 | 198 | 101 | 5.8 | 40 | 0.35 |
   Post-partum mastitis, USA [34] | 601 | 1239 | 56 | 59 | 3.8 | 28 | 0.43 |
 | No. of cancer survivors | Observed | Expected |  |  | RR/OE | |
Cancer survivors | Â | Â | Â | Â | Â | Â | Â |
   Pediatric HL (age < 16) LESG, USA [35]d | 480 |  | 29 | 0.7 | f | 11.7 | 55.5 |
   Childhood cancer, CCSS, USA [36]d | 6304 |  | 60 | 3.7 | f | 7.8 | 24.7h |
   Pediatric HL international [37] | 2737 |  | 52 | 3.7 | f | 16 | 14.1 |
   HL, UK [38]d | 2085 |  | 19 | 13.5 | f | - | 2.5h |
   Breast cancer, Denmark [39]e | 56,540 |  | 529e | - | 2.5 | 51 | 1.04 |
   Breast cancer, USA [40]e | 41,109 |  | 655e | - | 2.8 | 52 | 1.33 |